Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Sublingual Immunotherapy* ; Rhinitis, Allergic*/therapy; Humans ; Sweden ; Carbon Dioxide ; Desensitization, Immunologic/methods ; Travel ; Travel-Related Illness ; Tablets
    • Abstract:
      In Sweden, allergy immunotherapy (AIT) is available as either subcutaneous immunotherapy (SCIT) injections or sublingual immunotherapy (SLIT) tablets and is used to treat moderate-severe allergic rhinitis (AR). This study sought to determine treatment-related CO 2 emissions and travel times in Swedish patients receiving either SCIT or SLIT-tablets. A list of specialized Swedish AR clinics that administer AIT was determined, and respective co-ordinates retrieved. Swedish municipality population data were obtained from a national database. The mean distance from each Swedish municipality to the nearest AR clinic was calculated, adjusted using a detour index, and weighted by estimated patient population size. Transport modality data were obtained from a Swedish urban transport study and CO 2 emissions were obtained from Government sources. The mean number of annual SLIT-tablets and SCIT doses required were calculated based on product labels and clinical expert input. The annual number of healthcare professional interactions were layered into the model to estimate changes in mean patient travel time, distance, and travel-related CO 2 emissions associated with using SCIT versus SLIT-tablets. Mean annual travel-related CO 2 emissions were 410 tonnes (to two significant figures [s.f.]; standard deviation [SD] 90) with SLIT-tablets, versus 1700 tonnes (SD 380) for SCIT, resulting in mean annual savings of approximately 1300 tonnes (SD 290) of CO 2 if all AIT patients were to receive SLIT-tablets instead of SCIT, over 380 times greater than 2021 average Swedish CO 2 emissions per capita. Approximate mean annual travel times for patients taking SLIT-tablets were 66,500 h (three s.f.; SD 14,400), and 278,000 h (SD 60,200) for SCIT, resulting in mean annual savings of 211,000 h (SD 45,800) if all AIT patients were to receive SLIT-tablets instead of SCIT. Compared with SCIT injections, SLIT-tablets led to substantial reductions in treatment-related CO 2 emissions and travel times for Swedish patients.
      (© 2024. The Author(s).)
    • References:
      JAMA. 2017 Feb 14;317(6):591-593. (PMID: 28196239)
      Immunol Allergy Clin North Am. 2020 Feb;40(1):69-85. (PMID: 31761122)
      Allergy. 2021 Nov;76(11):3383-3389. (PMID: 34379805)
      Curr Environ Health Rep. 2017 Dec;4(4):504-513. (PMID: 29080073)
      Clin Exp Allergy. 1998 Nov;28 Suppl 5:45-9; discussion 50-1. (PMID: 9988447)
      Allergy. 2007;62 Suppl 85:17-25. (PMID: 17927674)
      Curr Allergy Asthma Rep. 2012 Apr;12(2):99-103. (PMID: 22287064)
      Immunotherapy. 2014;6(6):775-86. (PMID: 25186606)
      Allergy. 2006 Nov;61(11):1299-304. (PMID: 17002705)
      Allergy Asthma Immunol Res. 2010 Apr;2(2):65-76. (PMID: 20358020)
      Am J Rhinol Allergy. 2016 Jan-Feb;30(1):48-53. (PMID: 26867530)
      J Environ Public Health. 2012;2012:492405. (PMID: 22523505)
      Clin Exp Allergy. 1998 Jun;28 Suppl 2:3-10. (PMID: 9678821)
      Curr Allergy Asthma Rep. 2016 Feb;16(2):12. (PMID: 26758865)
      Ann Pharmacother. 2006 Jun;40(6):1162-9. (PMID: 16735653)
      World Allergy Organ J. 2021 Jul;14(7):100558. (PMID: 34122718)
      Indian J Otolaryngol Head Neck Surg. 2015 Jun;67(2):143-9. (PMID: 26075169)
      Br J Gen Pract. 2013 Sep;63(614):e595-603. (PMID: 23998839)
      J Allergy Clin Immunol Pract. 2013 Sep-Oct;1(5):455-7. (PMID: 24565616)
      Respir Res. 2009 Oct 12;10:94. (PMID: 19821983)
      Eur Ann Allergy Clin Immunol. 2003 Dec;35(10):386-92. (PMID: 14768524)
      Allergy. 2008 Apr;63 Suppl 86:8-160. (PMID: 18331513)
      Lancet Planet Health. 2020 Jul;4(7):e271-e279. (PMID: 32681898)
      NPJ Prim Care Respir Med. 2016 Feb 04;26:15082. (PMID: 26845513)
      J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S2-8. (PMID: 11449200)
      Clin Exp Allergy. 2004 Jan;34(1):38-43. (PMID: 14720260)
      Clin Respir J. 2012 Jul;6(3):159-68. (PMID: 21848956)
      Expert Rev Clin Immunol. 2021 Mar;17(3):255-268. (PMID: 33645387)
      Clin Med (Lond). 2016 Dec;16(6):584-587. (PMID: 27927826)
      J Thorac Dis. 2016 Jan;8(1):E31-40. (PMID: 26904251)
      Methods Mol Biol. 2021;2223:295-335. (PMID: 33226602)
      Eur Respir Rev. 2014 Jun;23(132):161-9. (PMID: 24881071)
      J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S45-53. (PMID: 11449206)
      Immunotherapy. 2022 Jun;14(8):627-638. (PMID: 35416072)
    • Accession Number:
      142M471B3J (Carbon Dioxide)
      0 (Tablets)
    • Publication Date:
      Date Created: 20240118 Date Completed: 20240122 Latest Revision: 20240122
    • Publication Date:
      20240122
    • Accession Number:
      PMC10796394
    • Accession Number:
      10.1038/s41598-024-51925-8
    • Accession Number:
      38238479